$0.61
0.82%
Downside
Day's Volatility :5.42%
Upside
4.64%
16.39%
Downside
52 Weeks Volatility :78.11%
Upside
73.82%
Period | Bioline Rx Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -6.69% | 0.0% |
6 Months | -50.38% | 0.0% |
1 Year | -71.72% | 0.0% |
3 Years | -78.01% | -22.3% |
Market Capitalization | 49.1M |
Book Value | $0.01 |
Earnings Per Share (EPS) | -0.45 |
PEG Ratio | 0.2 |
Wall Street Target Price | 9.83 |
Profit Margin | -176.67% |
Operating Margin TTM | -107.05% |
Return On Assets TTM | -35.23% |
Return On Equity TTM | -171.94% |
Revenue TTM | 17.0M |
Revenue Per Share TTM | 0.24 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -33.1M |
Diluted Eps TTM | -0.45 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.35 |
EPS Estimate Next Year | -0.38 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.1 |
What analysts predicted
Upside of 1511.48%
Sell
Neutral
Buy
Bioline Rx Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bioline Rx Ltd | -3.6% | -50.38% | -71.72% | -78.01% | -79.34% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bioline Rx Ltd | NA | NA | 0.2 | -0.35 | -1.72 | -0.35 | NA | 0.01 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bioline Rx Ltd | NA | $49.1M | -79.34% | NA | -176.67% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Bioline Rx Ltd
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 108.8%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 147.2%
Alyeska Investment Group, L.P.
CVI Holdings LLC
Morgan Stanley - Brokerage Accounts
Envestnet Asset Management Inc
Susquehanna International Group, LLP
Values First Advisors Inc
biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain content posted by a third party or links to third party websites (the “content” or “third party content”). this content is provided solely for general informational purposes as a convenience to you and not as an endorsement by the company of the content. it does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. the company is not responsible for this content and does not make any representations as to the subject matter, accuracy, completeness or timeliness or the content. if you decide to access linked third party websites, you do so at your own risk. there is no warranty of any kind, express or implied, regarding the content, including without limitation any warranty of m
Organization | Bioline Rx Ltd |
Employees | 79 |
CEO | Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.61
-0.23%
Keyarch Acquisition Corp
$0.61
-0.23%
Connexa Sports Technologies Inc
$0.61
-0.23%
Us Value Etf
$0.61
-0.23%
First Wave Biopharma Inc
$0.61
-0.23%
Global X Msci Next Emerging
$0.61
-0.23%
Fat Projects Acquisition Corp
$0.61
-0.23%
Capital Link Global Fintech
$0.61
-0.23%
Applied Uv Inc
$0.61
-0.23%